Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies.
Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome.Tranzyme Pharma is based in North Carolina, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 13, 2005 | Series A | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Pacific Rim Ventures | — | Series A |